Ariel López-Chávez

10.2k total citations · 1 hit paper
41 papers, 3.7k citations indexed

About

Ariel López-Chávez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ariel López-Chávez has authored 41 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Ariel López-Chávez's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). Ariel López-Chávez is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). Ariel López-Chávez collaborates with scholars based in United States, Germany and Italy. Ariel López-Chávez's co-authors include Alan Sandler, Mark A. Socinski, Gene Grant Finley, Marcin Kowanetz, Denis Moro‐Sibilot, Fabrice Barlési, Francesco Orlandi, Federico Cappuzzo, Naoyuki Nogami and Delvys Rodríguez‐Abreu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Ariel López-Chávez

40 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

2018 2.6k citations Mark A. Socinski, Robert M. Jotte et al. profile →

Peers

Ariel López-Chávez

ONCOL

PRM

IMMUN

Joshua K. Sabari United States

J. Thaddeus Beck United States

Biagio Ricciuti United States

Ernest Nadal Spain

Rita Chiari Italy

Hiroyasu Kaneda Japan

Dariusz M. Kowalski Poland

Giulio Metro Italy

Scott Cruickshank United States

Yoichi Naito Japan

Joshua K. Sabari United States

Ariel López-Chávez

2.2k ×0.8

ONCOL

1.4k ×0.7

PRM

1.0k ×1.2

295 ×0.5

IMMUN

458 ×1.0

Citations per year, relative to Ariel López-Chávez Ariel López-Chávez (= 1×) peers Joshua K. Sabari

Countries citing papers authored by Ariel López-Chávez

Since Specialization

Citations

This map shows the geographic impact of Ariel López-Chávez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ariel López-Chávez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ariel López-Chávez more than expected).

Fields of papers citing papers by Ariel López-Chávez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ariel López-Chávez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ariel López-Chávez. The network helps show where Ariel López-Chávez may publish in the future.

Co-authorship network of co-authors of Ariel López-Chávez

This figure shows the co-authorship network connecting the top 25 collaborators of Ariel López-Chávez. A scholar is included among the top collaborators of Ariel López-Chávez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ariel López-Chávez. Ariel López-Chávez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reck, Martin, Mark A. Socinski, Federico Cappuzzo, et al.. (2017). Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150). Annals of Oncology. 28. xi31–xi31. 32 indexed citations

Jassem, Jacek, Filippo de Marinis, David R. Spigel, et al.. (2017). IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC. Annals of Oncology. 28. ii50–ii50. 3 indexed citations

Liu, Stephen V., Martin Reck, Tony Mok, et al.. (2017). P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC. Journal of Thoracic Oncology. 12(1). S1299–S1299. 1 indexed citations

Horn, Leora, Martin Reck, Tony Mok, et al.. (2016). PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC. Journal of Thoracic Oncology. 11(11). S305–S306. 3 indexed citations

Herbst, Roy S., Filippo de Marinis, Jacek Jassem, et al.. (2016). PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients. Journal of Thoracic Oncology. 11(11). S304–S305. 4 indexed citations

Horn, Leora, Martin Reck, Tony Mok, et al.. (2016). A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133). Annals of Oncology. 27. vi496–vi496. 3 indexed citations

Marinis, Filippo de, Jacek Jassem, David R. Spigel, et al.. (2016). 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts). Annals of Oncology. 27. ix154–ix154. 4 indexed citations

Herbst, Roy S., Filippo de Marinis, Jacek Jassem, et al.. (2015). 355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC. Annals of Oncology. 26. ix103–ix103. 3 indexed citations

Thomas, Anish, Arun Rajan, Éva Szabó, et al.. (2014). A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. Clinical Cancer Research. 20(21). 5392–5402. 79 indexed citations

10.

Gerber, David E., Suresh S. Ramalingam, Daniel Morgensztern, et al.. (2014). A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.. Journal of Clinical Oncology. 32(15_suppl). TPS8126–TPS8126. 5 indexed citations

11.

Sullivan, Donald R., Linda Ganzini, Jonathan P. Duckart, et al.. (2013). Treatment Receipt and Outcomes among Lung Cancer Patients with Depression. Clinical Oncology. 26(1). 25–31. 31 indexed citations

12.

Rajan, Arun, Sean Khozin, Anish Thomas, et al.. (2013). The Evaluation of Selumetinib a MEK-Inhibitor with and without the Addition of Erlotinib in KRAS Mutated Non-Small Cell Lung Cancer. Annals of Oncology. 24. i7–i7. 1 indexed citations

13.

Kelly, Ronan J., Anish Thomas, Arun Rajan, et al.. (2013). A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Annals of Oncology. 24(10). 2601–2606. 128 indexed citations

14.

Neary, Nicola M., Ariel López-Chávez, Brent S. Abel, et al.. (2012). Neuroendocrine ACTH-Producing Tumor of the Thymus—Experience with 12 Patients over 25 Years. The Journal of Clinical Endocrinology & Metabolism. 97(7). 2223–2230. 49 indexed citations

15.

Henry, Cassandra L., Ariel López-Chávez, Laura P. Stabile, & Jill M. Siegfried. (2012). HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF. PubMed. 1(1). 52–63.

16.

López-Chávez, Ariel, Larry Leon, Joan H. Schiller, et al.. (2012). Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis. Journal of Thoracic Oncology. 7(11). 1707–1712. 41 indexed citations

17.

Kelly, Ronan J., Arun Rajan, Jeremy Force, et al.. (2011). Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research. 17(5). 1190–1199. 58 indexed citations

18.

Kelly, Ronan J., Ariel López-Chávez, Deborah E. Citrin, John E. Janik, & John C. Morris. (2011). Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Molecular Cancer. 10(1). 35–35. 131 indexed citations

19.

Kelly, Ronan J., Ariel López-Chávez, & Éva Szabó. (2011). Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials. Current Drug Targets. 12(13). 1983–1988. 2 indexed citations

20.

López-Chávez, Ariel, Ricardo Miledi, & Ataúlfo Martı́nez-Torres. (2005). Cloning and functional expression of the bovine GABAC ρ2 subunit. Neuroscience Research. 53(4). 421–427. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact